Citicoline reaches parents of autistic children through a chain of reasoning that sounds coherent: citicoline supplies choline, choline feeds acetylcholine synthesis, cholinergic signaling is implicated in social and attentional processing, and animal work has reported behavioral improvements. That chain has now been tested at the only point that matters, in a randomized trial in autistic children, and the result is the one that supplement pages rarely mention.
Nothing here constitutes medical advice. Citicoline has not been approved by the FDA to diagnose, treat, cure, or prevent autism spectrum disorder or any other condition. Autism care decisions belong with a developmental pediatrician or pediatric neurologist who knows the child.
Key Takeaways
- A 2025 randomized, open-label trial in 101 children with autism spectrum disorder found no significant difference between citicoline and control on either symptom scale used, after two months [1].
- The trial found no benefit on any subscale of the Gilliam Autism Rating Scale, not just on the total score [1].
- Its authors concluded that prescribing citicoline for autistic children “should be discouraged” absent better evidence [1].
- The citicoline was given as an intramuscular injection at 10 mg/kg, not as an oral capsule or powder [1].
- The supporting animal work used a thimerosal-exposure mouse model [2], a premise that human epidemiology does not support as a cause of autism.
- Citicoline does have a positive attention finding in adolescents, but in healthy adolescent males, not autistic ones, in a study co-authored by employees of the ingredient manufacturer [3].
The One Trial That Tested This Directly
In 2025, a group at Shiraz University of Medical Sciences in Iran published a randomized, open-label, parallel-design clinical trial in the Journal of Autism and Developmental Disorders. It enrolled 101 children under 18 with autism spectrum disorder across two clinical sites, assigning 45 to citicoline and 56 to a control group [1].
Symptoms were measured with two age-appropriate instruments: the Modified Checklist for Autism in Toddlers for children under three, and the Gilliam Autism Rating Scale for children over three. Both were administered before treatment and again after two months [1].
At baseline the groups did not differ significantly on either scale. After two months of treatment, they still did not. The reported p-values were 0.188 for the toddler checklist and 0.269 for the Gilliam scale, neither anywhere near conventional significance [1]. The authors went further and looked at the Gilliam subscales individually, which is where a real but narrow effect would show up if one existed. Citicoline did not show a benefit on any of them [1].
Their conclusion is unusually direct for a clinical paper. They wrote that there is not enough evidence to support prescribing citicoline for children with autism spectrum disorder, and that the practice should be discouraged unless higher-quality evidence emerges to the contrary [1].
Why the Open-Label Design Makes This More Convincing, Not Less
Open-label means nobody was blinded: the families and the assessors knew which children were receiving citicoline. Ordinarily that is a weakness, and it is worth naming as one. But it cuts in a specific direction here. Unblinded designs systematically bias results toward the active treatment, because expectation shapes how caregivers and raters score behavior, and autism rating scales depend heavily on caregiver report.
So this trial had its thumb on the scale in citicoline’s favor and still found nothing. A negative result from an unblinded study is harder to explain away than a negative result from a blinded one. It does not prove citicoline is useless in autism, but it does mean the burden of proof has not been met, and that the easiest way to have met it was already available.
The Route Matters, in an Unusual Direction
The children received citicoline at 10 mg/kg intramuscularly [1]. That is an injection, given in a clinic, not the oral capsule or powder anyone would buy as a supplement.
On most of this site, a topical or injected route means the study cannot be used to justify oral supplements, because the delivered exposure is higher and more direct than swallowing achieves. That logic still applies. But the conclusion runs the other way for a negative result: injected citicoline bypasses first-pass metabolism in the gut wall and liver entirely, delivering the compound under conditions at least as favorable as an oral dose. If a route that favorable produced no measurable signal over two months, there is no basis for expecting a capsule to do better. A negative result from the stronger route is the more damaging kind of negative result.
The dose deserves a note too. At 10 mg/kg, a 30 kg child received about 300 mg. Whether a higher dose or a longer course would behave differently is untested, and the trial cannot answer it.
Where the Positive Expectation Came From
Two threads feed the idea that citicoline should help.
The first is animal work. A 2024 study in International Immunopharmacology gave newborn mice injections of thimerosal, then treated them with citicoline at 250 or 500 mg/kg for three weeks. The treated mice showed less brain damage on histopathology, along with changes in alpha-7 nicotinic receptor expression, higher hippocampal acetylcholine, lower oxidative stress markers, lower caspase-3, and lower inflammatory cytokines [2]. As biochemistry, that is a coherent set of findings.
Its limitation is the model itself. The paradigm induces autism-like behavior in mice through thimerosal exposure, and thimerosal exposure has been examined extensively in human populations without being established as a cause of autism. An animal model built on a mechanism that does not appear to operate in humans can still generate useful pharmacology, but it cannot carry an inference about treating human autism. The mice in that study were also given citicoline by intraperitoneal injection at doses far above anything a person takes orally.
The second thread is a 2012 Spanish review of X-linked ichthyosis associated with the Xp22.31 microdeletion, a genetic syndrome that can present alongside epilepsy, hyperactivity, and autism. It notes that improvements were observed following citicoline treatment, attributed to citicoline’s role in structural phospholipid synthesis [4]. That is an observation within a specific chromosomal deletion syndrome, described in a review rather than tested in a controlled study. It is not evidence about autism generally.
The Adolescent Attention Study Is Real, and Is About Something Else
Citicoline does have a positive randomized finding in young people. Seventy-five healthy adolescent males received 250 mg, 500 mg, or placebo for 28 days, and the citicoline groups showed improved attention (p = 0.02), increased psychomotor speed (p = 0.03), and decreased impulsivity (p = 0.01), with higher weight-adjusted doses predicting better accuracy [3].
Two things keep this from transferring. The participants were healthy adolescents with no autism diagnosis, and improving attention in a neurotypical teenager is a different claim from changing core autism features such as social communication and repetitive behavior. The study was also co-authored by employees of Kyowa Hakko, which manufactures the branded Cognizin citicoline used in it [3]. That does not make the result wrong, and the disclosure was made properly, but industry authorship on a positive nutraceutical finding is a fact a reader should have.
What a Parent Can Reasonably Take From This
The honest summary is short. One randomized trial has tested citicoline in autistic children. It used a delivery route more favorable than a supplement, ran for two months, measured with standard instruments, was unblinded in a way that should have favored the treatment, and found no effect on anything it looked at, including every individual subscale. Its authors recommended against the practice.
Supporting evidence sits in a mouse model whose premise is not supported in humans, and in a positive attention study conducted in healthy teenagers. Neither fills the gap. Citicoline is generally well tolerated, but tolerability is not efficacy, and money and caregiver attention spent on an intervention with a negative trial behind it are not available for approaches that do have evidence. Any decision about supplements for an autistic child belongs in a conversation with that child’s clinician, particularly where seizures or other medications are in the picture.
Frequently Asked Questions
Does citicoline help autism?
The only randomized trial to test it, in 101 autistic children over two months, found no significant benefit on either symptom scale used or on any subscale, and its authors concluded that the practice should be discouraged absent better evidence [1].
Was the trial testing the same citicoline sold as a supplement?
Not in the same form. The children received citicoline as an intramuscular injection at 10 mg/kg [1]. Injection delivers the compound under conditions at least as favorable as an oral capsule, so a null result there gives no reason to expect more from a capsule.
What about the studies showing citicoline improved autistic behavior in mice?
A 2024 mouse study did report reduced brain damage and improved markers after citicoline [2], but it used a thimerosal-exposure model, and thimerosal exposure is not established as a cause of autism in humans. The doses were also injected and far above human oral intake.
Does citicoline improve attention in teenagers?
In healthy adolescent males, a 28-day randomized study found improved attention, faster psychomotor speed, and reduced impulsivity versus placebo [3]. Those participants were not autistic, and the study was co-authored by employees of the company that makes the branded citicoline used.
Is citicoline safe for children?
The autism trial reported no safety problem that stopped the study, and citicoline is generally described as well tolerated, but tolerability is a separate question from benefit and none of this replaces a pediatric clinician’s judgment, especially for a child taking other medication or with a seizure history.
References
- Zare S, Reihani H, Taghizadeh Sarvestani R, Inaloo S, Nemati H, Asadi-Pooya AA. Effects of Citicoline in Children with Autism Spectrum Disorder: A Randomized, Open-label Clinical Trial. J Autism Dev Disord (2025). PMID 40576847
- Khattab NA, El-Kadem AH, Elblehi SS, Ahmed El-Mahdy N, El-Shitany NA. The emerging role of alpha7nAChRs/caspase-3/Nrf-2 signaling pathway in citicoline improved autistic behavior induced by thimerosal in mice. Int Immunopharmacol (2024). PMID 38401462
- McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, Yurgelun-Todd D. The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males. J Atten Disord (2019). PMID 26179181
- Carrascosa-Romero MC, Suela J, Alfaro-Ponce B, Cepillo-Boluda AJ. X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion. Rev Neurol (2012). PMID 22314765
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
